BWAY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

16.265

Open

16.265

VWAP

15.84

Vol

121.26K

Mkt Cap

627.72M

Low

15.580

Amount

1.92M

EV/EBITDA(TTM)

--

Total Shares

40.03M

EV

562.09M

EV/OCF(TTM)

--

P/S(TTM)

--

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Show More

Events Timeline

(ET)

2026-03-19

08:00:00

BrainsWay Completes $1M Investment in Axis

2026-03-11 (ET)

2026-03-11

16:30:00

Dow and S&P 500 Close Lower Amid Oil Price Volatility

2026-03-11

12:00:00

Dow Jones Drops Over 400 Points Amid Oil Price Volatility

2026-03-11

07:40:00

BrainsWay Q4 Revenue $14.5M, Exceeds Consensus

2026-03-11

07:40:00

Company Anticipates Operating Income of 13% to 14%

2026-03-04 (ET)

2026-03-04

07:50:00

BrainsWay Unveils New Clinical Data, Depression Treatment Reduced to 6 Days

2026-02-19 (ET)

2026-02-19

07:50:00

BrainsWay Enters Strategic Financing Agreement with BrainStim

2026-02-18 (ET)

2026-02-18

07:40:00

BrainsWay Comments on Evernorth's Elimination of TMS Prior Authorization

2026-02-17 (ET)

2026-02-17

07:50:00

BrainsWay Adjusts ADS Ratio to 1:1

News

Newsfilter

04-15Newsfilter

BrainsWay Advances TMS Treatment Coverage Policy Changes

Yahoo Finance

04-13Yahoo Finance

BrainsWay to Present at 25th Annual Needham Virtual Healthcare Conference

Newsfilter

03-26Newsfilter

BrainsWay Completes $6 Million Investment in Neurolief Following FDA Approval

moomoo

BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD

Yahoo Finance

03-12Yahoo Finance

Major Averages Decline Amid Oil Price Volatility

Benzinga

Wall Street Analysts Adjust MU Stock Ratings

3 Analyst Rating

Wall Street analysts forecast BWAY stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

26.33

High

30.00

Current: 0.000

Low

19.00

Averages

26.33

High

30.00

H.C. Wainwright

Buy

downgrade

$30 -> $15

AI Analysis

2026-03-12

Reason

H.C. Wainwright

Price Target

$30 -> $15

AI Analysis

2026-03-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Brainsway to $15 from $30 and keeps a Buy rating on the shares to reflect the recent change effected in the ratio of American Depositary Shares to ordinary shares. Previously, this ratio was one ADS for every two ordinary shares, but earlier this month it was revised to a one-to-one ratio, the analyst noted. In the wake of a "solid performance in 2025, the firm sees a positive medium- to long-term outlook, the analyst tells investors.

H.C. Wainwright

H.C. Wainwright

maintain

$24 -> $30

2026-01-26

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$24 -> $30

2026-01-26

maintain

Reason

H.C. Wainwright raised the firm's price target on Brainsway to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for Neurolief's Proliv RX system, a class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BWAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Brainsway Ltd (BWAY.O) is 75.19, compared to its 5-year average forward P/E of 38.92. For a more detailed relative valuation and DCF analysis to assess Brainsway Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

38.92

Current PE

75.19

Overvalued PE

125.65

Undervalued PE

-47.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

1.65

Current EV/EBITDA

45.08

Overvalued EV/EBITDA

15.55

Undervalued EV/EBITDA

-12.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.42

Current PS

7.54

Overvalued PS

4.97

Undervalued PS

1.86

Financials

AI Analysis

Annual

Quarterly

Whales Holding BWAY

More Investment House Ltd.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Brainsway Ltd (BWAY) stock price today?

The current price of BWAY is 15.68 USD — it has decreased -0.82

What is Brainsway Ltd (BWAY)'s business?

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

What is the price predicton of BWAY Stock?

Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is26.33 USD with a low forecast of 19.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Brainsway Ltd (BWAY)'s revenue for the last quarter?

Brainsway Ltd revenue for the last quarter amounts to 13.51M USD, increased 28.66

What is Brainsway Ltd (BWAY)'s earnings per share (EPS) for the last quarter?

Brainsway Ltd. EPS for the last quarter amounts to 0.04 USD, increased 100.00

How many employees does Brainsway Ltd (BWAY). have?

Brainsway Ltd (BWAY) has 120 emplpoyees as of April 21 2026.

What is Brainsway Ltd (BWAY) market cap?

Today BWAY has the market capitalization of 627.72M USD.